BEONE MEDICINES: Approximately 95% of Pancreatic Cancer Cases Show KRAS Mutation, Around 20% Exhibit MTAP Deletion, Enabling Easy Identification of Overlapping Patient Groups

Deep News08-07

BEONE MEDICINES stated during a research briefing that both MTAP deletions and KRAS mutations are high-frequency molecular events in human tumors, theoretically offering numerous opportunities for combination therapies.

In pancreatic cancer, the KRAS mutation rate is approximately 95%, while the MTAP deletion rate is about 20%, making the overlapping patient population relatively easy to identify.

In lung adenocarcinoma, the KRAS mutation rate is around 30% in Western populations and roughly 10% in Chinese populations. When combined with MTAP deletions, the target population becomes significantly smaller.

The company intends to conduct exploratory research in lung cancer, while for other tumor types, priority will be determined primarily based on the overlap rate of the two mutations and early clinical signals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment